The Controversy Concerning Plasma Homocysteine in Parkinson Disease Patients Treated with Levodopa Alone or with Entacapone
2006; Lippincott Williams & Wilkins; Volume: 29; Issue: 3 Linguagem: Inglês
10.1097/01.wnf.0000220817.94102.95
ISSN1537-162X
AutoresTheresa A. Zesiewicz, Lynn Wecker, Kelly L. Sullivan, Lisa R. Merlin, Robert A. Hauser,
Tópico(s)Dysphagia Assessment and Management
ResumoLevodopa treatment of Parkinson disease results in hyperhomocysteinemia (HHcy) as a consequence of levodopa methylation by catechol-O-methyltransferase (COMT). Although inhibition of COMT should theoretically prevent or reduce levodopa-induced HHcy, results from several prospective studies are conflicting. Our review of these studies suggests that the ability of COMT inhibition to reduce or prevent levodopa-induced HHcy in Parkinson disease patients may be attributed to differences in the vitamin status of the study participants. In patients with low or low-normal folate levels, levodopa administration is associated with a greater increase in homocysteine and concomitant entacapone administration is associated with a greater reduction in homocysteine.
Referência(s)